Literature DB >> 9326433

Reduced cholesterol is associated with recent minor illness: the CARDIA Study. Coronary Artery Risk Development in Young Adults.

D R Jacobs1, B Hebert, P J Schreiner, S Sidney, C Iribarren, S Hulley.   

Abstract

Lower levels of plasma total cholesterol have been observed during severe infection, but it is not known whether the minor illnesses encountered in the general population are also associated with reduced cholesterol. This paper examines the relation between minor illness and plasma lipids, using 7- and 10-year follow-up data from more than 3,000 generally healthy participants in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. At both 7 and 10 years, approximately 8.5% of participants stated they had been "ill with cold, flu, fever, or vomiting in the past 24 hours." In both cross-sectional and longitudinal analyses, the plasma total cholesterol was about 5 mg/dl lower (p < 0.006) and high density lipoprotein cholesterol about 1.2 mg/dl lower (p < 0.12) in those who reported minor illness than in those who did not. Plasma triglycerides did not vary with minor illness. The authors conclude that reductions in plasma total, low density, and high density lipoprotein cholesterol mark an acute phase response even during minor illness. These reductions may bias surveys over a limited geographic area during a short period because the proportion with minor illness may vary locally. Because this effect should be stronger with more precise illness diagnosis, clinicians should avoid making measurements for cholesterol management when illness may alter plasma lipid levels and the resulting decisions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326433     DOI: 10.1093/oxfordjournals.aje.a009314

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  8 in total

1.  Cholesterol and coronary heart disease: screening and treatment.

Authors:  S Ebrahim; G D Smith; C McCabe; N Payne; M Pickin; T A Sheldon; F Lampe; F Sampson; S Ward; G Wannamthee
Journal:  Qual Health Care       Date:  1998-12

2.  Maternal lipids at mid-pregnancy and the risk of preterm delivery.

Authors:  Lanay M Mudd; Claudia B Holzman; Janet M Catov; Patricia K Senagore; Rhobert W Evans
Journal:  Acta Obstet Gynecol Scand       Date:  2012-05-01       Impact factor: 3.636

3.  Prepregnancy lipids related to preterm birth risk: the coronary artery risk development in young adults study.

Authors:  Janet M Catov; Roberta B Ness; Melissa F Wellons; David R Jacobs; James M Roberts; Erica P Gunderson
Journal:  J Clin Endocrinol Metab       Date:  2010-05-25       Impact factor: 5.958

Review 4.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Kirsten Ward; Theresa Hm Moore; Margaret Burke; George Davey Smith; Juan-Pablo Casas; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

5.  Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile.

Authors:  L J Murray; D P O'Reilly; G M Ong; C O'Neill; A E Evans; K B Bamford
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

Review 6.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

7.  Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer.

Authors:  Jiyoung Ahn; Unhee Lim; Stephanie J Weinstein; Arthur Schatzkin; Richard B Hayes; Jarmo Virtamo; Demetrius Albanes
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-11-03       Impact factor: 4.254

Review 8.  Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes.

Authors:  Enas A Enas; Arun Kuruvila; Pravien Khanna; C S Pitchumoni; Viswanathan Mohan
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.